Dactolisib (BEZ235)

For research use only. Not for use in humans.

目录号：S1009 别名： NVP-BEZ235

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
100mg	RMB 1414.41	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dactolisib (BEZ235)发表文献258篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )
Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )
Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )
BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )
J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )
Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MUDBcpRqdWmlcn;ibYFtKEG\|c3H5		MUixPEBp	NIHWNVNFVVOR	MnXMRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	NYXaXGpsOjR6MEW5OFY>
MCF7	NWXRWGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv4ZZV[OC5yMT2xNFAh\|ryP	MmjROFghcA>?	MkKzSG1UVw>?	NXviVZlyUUN3ME2wMlc{KM7:TR?=	MkL5NlM5PzF7MES=
HCT116	NF\1U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\tNVAvODFvMUCwJO69VQ>?	MlrhOFghcA>?	NF:3[VNFVVOR	NXr6dVRjUUN3ME2xMlE3KM7:TR?=	NYnzSWR6OjN6N{G5NFQ>
U87MG	NYDVdoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYmwMlAyNTFyMDFOwG0>	MVK0PEBp	NE\KOYVFVVOR	NHrMRVBKSzVyPUGuN\|Ih\|ryP	NFrUPIUzOzh5MUmwOC=>
HBC4	NVPyNXJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LxOFAvODFvMUCwJO69VQ>?	M2Dx[FQ5KGh?		NF3NeG5Nd2diR1m1NF0uQC54MTDN	MofkNlI{OzZ{NE[=
BSY1	NFvtPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjkNE4xOS1zMECg{txO	M{\3VFQ5KGh?		NUDNNIt1VG:pIFfJOVA:NThwNEigUS=>	M4\aclIzOzN4MkS2
HBC5	M2DBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuwMlAyNTFyMDFOwG0>	NIDS[G81QCCq		NGr4bHZNd2diR1m1NF0uPy56NzDN	MkHtNlI{OzZ{NE[=
MCF7	NU\BVZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXhcnFyOC5yMT2xNFAh\|ryP	MX[0PEBp		MkDOUI9oKEeLNUC9MVgvOTZiTR?=	MWiyNlM{PjJ2Nh?=
MDA-MB-231	NF;rN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4S4dFAvODFvMUCwJO69VQ>?	MX60PEBp		MofVUI9oKEeLNUC9MVgvODliTR?=	MXqyNlM{PjJ2Nh?=
U251	NEi0dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjYPJNNOC5yMT2xNFAh\|ryP	MXy0PEBp		M4C1OWxw\yCJSUWwQU04NjZ4IF2=	MkjZNlI{OzZ{NE[=
SF268	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkewNE4xOS1zMECg{txO	M{LRUVQ5KGh?		NXuzcWYxVG:pIFfJOVA:NTdwOUKgUS=>	M2DyWlIzOzN4MkS2
SF295	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPmNE4xOS1zMECg{txO	MknJOFghcA>?		MUTMc4chT0l3ME2tPE4{OSCP	M3fzOVIzOzN4MkS2
SF539	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;XNE4xOS1zMECg{txO	MU[0PEBp		NYXyT5g2VG:pIFfJOVA:NThwNUmgUS=>	NFfX[lczOjN\|NkK0Oi=>
SNB75	NIC4VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmriNE4xOS1zMECg{txO	MVe0PEBp		MnS1UI9oKEeLNUC9MVgvPThiTR?=	MkjtNlI{OzZ{NE[=
SNB78	NFPmeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6wMlAyNTFyMDFOwG0>	NIHlOnI1QCCq		M2TUTWxw\yCJSUWwQU05NjZ3IF2=	MoPINlI{OzZ{NE[=
HCC2998	M4\QcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEj5boExNjBzLUGwNEDPxE1?	NF\pflQ1QCCq		NYK3TIFIVG:pIFfJOVA:NThwMEWgUS=>	M2TTOlIzOzN4MkS2
KM12	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzENE4xOS1zMECg{txO	MWO0PEBp		Moq4UI9oKEeLNUC9MVcvPTRiTR?=	NHH3UogzOjN\|NkK0Oi=>
HT-29	NIjCTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj1OoJxOC5yMT2xNFAh\|ryP	M1u3U\|Q5KGh?		NW\6dYM1VG:pIFfJOVA:NTdwN{WgUS=>	NGrZZnMzOjN\|NkK0Oi=>
HCT15	NUHxd412T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XxPFAvODFvMUCwJO69VQ>?	MnfUOFghcA>?		MVLMc4chT0l3ME2tPE4xOyCP	MUKyNlM{PjJ2Nh?=
HCT116	M2XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[wMlAyNTFyMDFOwG0>	M1jDNlQ5KGh?		Ml7GUI9oKEeLNUC9MVcvPjFiTR?=	NXLPNmQ{OjJ\|M{[yOFY>
NCI-H23	NHjOVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXOwMlAyNTFyMDFOwG0>	NXfL[WNvPDhiaB?=		MYHMc4chT0l3ME2tO{43PCCP	NXjBUnljOjJ\|M{[yOFY>
NCI-H226	NHvJZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M123flAvODFvMUCwJO69VQ>?	Mnv1OFghcA>?		MYDMc4chT0l3ME2tPE41PCCP	NV\heotoOjJ\|M{[yOFY>
NCI-H522	NWHDbm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LrflAvODFvMUCwJO69VQ>?	NF3RZ5I1QCCq		NGPDUGZNd2diR1m1NF0uQC52NTDN	NW\3N2RoOjJ\|M{[yOFY>
NCI-H438	NITMRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkKzNE4xOS1zMECg{txO	NGrJXW01QCCq		Mn;FUI9oKEeLNUC9MVgvOTFiTR?=	MUCyNlM{PjJ2Nh?=
A549	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3xRWd3OC5yMT2xNFAh\|ryP	M3TUdFQ5KGh?		MYPMc4chT0l3ME2tPE4xPyCP	Mn3XNlI{OzZ{NE[=
DMS273	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[xNE4xOS1zMECg{txO	NU\LcFd2PDhiaB?=		NVr6eYpjVG:pIFfJOVA:NTdwOECgUS=>	NIDUcVYzOjN\|NkK0Oi=>
DMS114	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTmNE4xOS1zMECg{txO	MYS0PEBp		M{KwRWxw\yCJSUWwQU05NjN7IF2=	MV6yNlM{PjJ2Nh?=
LOXIMVI	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlntNE4xOS1zMECg{txO	NXLpRod{PDhiaB?=		M3vxZWxw\yCJSUWwQU05NjZ4IF2=	MUOyNlM{PjJ2Nh?=
OVCAR3	NIDHOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7HXWpLOC5yMT2xNFAh\|ryP	MknJOFghcA>?		NV\RNpZZVG:pIFfJOVA:NThwMUegUS=>	M4GzWVIzOzN4MkS2
OVCAR4	NVHWfWhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW2NE4xOS1zMECg{txO	M2DxNVQ5KGh?		NIPnb4tNd2diR1m1NF0uQC53ODDN	MYqyNlM{PjJ2Nh?=
OVCAR5	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHINE4xOS1zMECg{txO	MYG0PEBp		NVnOcJVlVG:pIFfJOVA:NTdwNUegUS=>	MXSyNlM{PjJ2Nh?=
OVCAR8	NHrUPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOwMlAyNTFyMDFOwG0>	MWq0PEBp		NXLHVZI6VG:pIFfJOVA:NTdwOESgUS=>	NVj6PIlLOjJ\|M{[yOFY>
SKOV3	M1vqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPDUYwxNjBzLUGwNEDPxE1?	MYe0PEBp		NX;hSnlOVG:pIFfJOVA:NThwNEGgUS=>	NYLLPGdGOjJ\|M{[yOFY>
RXF631L	NYLCSIJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;UbGQxNjBzLUGwNEDPxE1?	M{TSXlQ5KGh?		NEPNWJRNd2diR1m1NF0uQC5{MTDN	NGDUPZQzOjN\|NkK0Oi=>
ACHN	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG4TWQxNjBzLUGwNEDPxE1?	NFvmbmw1QCCq		NFL4PWJNd2diR1m1NF0uPy57NTDN	M2TwblIzOzN4MkS2
St-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y0UlAvODFvMUCwJO69VQ>?	MmPZOFghcA>?		MmnrUI9oKEeLNUC9MVcvPDdiTR?=	NUHyO4tyOjJ\|M{[yOFY>
MKN1	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEW4Sm4xNjBzLUGwNEDPxE1?	M3HmdVQ5KGh?		NFTPXFBNd2diR1m1NF0uQC52MTDN	MVWyNlM{PjJ2Nh?=
MKN7	NHn0N5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUK5NWIyOC5yMT2xNFAh\|ryP	MVi0PEBp		NG\zUnZNd2diR1m1NF0uPy54ODDN	MX2yNlM{PjJ2Nh?=
MKN28	M1fMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWewMlAyNTFyMDFOwG0>	M1XsNlQ5KGh?		NIXXO3FNd2diR1m1NF0uPy5yNzDN	M{jLW\|IzOzN4MkS2
MKN45	NVjnc5pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPJNE4xOS1zMECg{txO	NHj2XnA1QCCq		NHHyZZFNd2diR1m1NF0uQC5\|NDDN	NXrZbm1iOjJ\|M{[yOFY>
MKN74	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\yNE4xOS1zMECg{txO	MnT4OFghcA>?		NEPWfm5Nd2diR1m1NF0uPy52MjDN	MoLLNlI{OzZ{NE[=
DU145	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jPe\|AvODFvMUCwJO69VQ>?	MVu0PEBp		Mkn2UI9oKEeLNUC9MVgvOTZiTR?=	NHTRPWczOjN\|NkK0Oi=>
PC3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13iUVAvODFvMUCwJO69VQ>?	MkLNOFghcA>?		MX;Mc4chT0l3ME2tPE43PiCP	MWGyNlM{PjJ2Nh?=
Trypanosoma brucei brucei	NVX2NnlkTnWwY4Tpc44hSXO\|YYm=	NV7DOnhLOjByIH7N	MUixNkBp	MoDXSG1UVw>?	NV:zbYdFTGWlcnXhd4UhcW5icHjvd5Bpd3SrZInsJIlvd3OrdH;sJJBpd3OyaHH0[UBt\X[nbB?=	NGL6TmgzPDhyNUm0Oi=>
Trypanosoma brucei brucei	MlfFSpVv[3Srb36gRZN{[Xl?		NXi1W3V4OThiaB?=	NGrUXW9FVVOR	NUTKZYJTUW6qaXLpeIlwdiCxZjDy[YNmeHSxcj3t[YRq[XSnZDDlcoRw[3m2b4Ppd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjD0doFve2[ncoLpckB2eHSja3W=	M2q4[VI1QDB3OUS2
Trypanosoma brucei brucei	NXrUZ\|ZVTnWwY4Tpc44hSXO\|YYm=	M4rkd\|IxOCCwTR?=	M1\pVFEzKGh?	MX7EUXNQ	NETxNppG\m[nY4Sgc44he3CqaX7nc416dGWrbjDs[ZZmdA>?	Mm\JNlQ5ODV7NE[=
Trypanosoma brucei brucei	MWjGeY5kfGmxbjDBd5NigQ>?	NYHYV2VkOjByIH7N	MYOxNkBp	NHrsPJZFVVOR	MVHF[oZm[3Rib36gdIhwe3CqYYTp[Jlt[2ixbHnu[UBt\X[nbB?=	NHHkdZQzPDhyNUm0Oi=>
UM-UC-3	M1LIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\pbmJzUUN3ME2zNVUheE1?	M1zpenNCVkeHUh?=
SBC-1	NYLnZY4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTd2MjDwUS=>	NF7WV5pUSU6JRWK=
MKN1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHsTWM2OD1{Lkigcm0>	NYjYUpdoW0GQR1XS
NCI-H720	NXrPXWV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3HOnhKSzVyPUOuOVchdk1?	M1\JUXNCVkeHUh?=
BFTC-909	NYPNR2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\DTWM2OD1\|LkexJI5O	MlvUV2FPT0WU
BPH-1	NYm3[WxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfLb\|NVUUN3ME20Mlc3KG6P	NVn5R4M3W0GQR1XS
PC-3	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLqTWM2OD13LkC5JI5O	NYLLblVbW0GQR1XS
AN3-CA	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwNU[gcm0>	MkTKV2FPT0WU
HN	NEDZZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mor2TWM2OD13Lkm2JI5O	NWDDdI9JW0GQR1XS
HCC2218	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[yNoZKSzVyPU[uOlEhdk1?	NYTDd5BRW0GQR1XS
KP-4	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[z[2lEPTB;NzDuUS=>	MkDRV2FPT0WU
LU-139	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjWTWM2OD15Lke3JI5O	MmTlV2FPT0WU
ETK-1	NIjZR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLNTWM2OD15Lki4JI5O	NV7yT5JmW0GQR1XS
Ramos-2G6-4C10	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDUSHJKSzVyPUiuOFkhdk1?	MljZV2FPT0WU
MHH-PREB-1	NV\yUlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTlwMUKgcm0>	MXnTRW5ITVJ?
DU-4475	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPhT5pKSzVyPUmuOFQhdk1?	MlXjV2FPT0WU
NCI-H1666	M1LRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELTW49KSzVyPUmuO\|Ehdk1?	MnnYV2FPT0WU
CAMA-1	NEjlRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTlwODDuUS=>	NVywbWkzW0GQR1XS
TYK-nu	M3\hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTlwOUSgcm0>	MVHTRW5ITVJ?
MFE-280	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoqwTWM2OD17Lkm5JI5O	NVLwSlNWW0GQR1XS
A549	M3PUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVf6WVNTUUN3ME2xNE4yPCCwTR?=	M4LVWHNCVkeHUh?=
769-P	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nxWGlEPTB;MUCuOFQhdk1?	MkD5V2FPT0WU
L-363	NEfHb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnqyTWM2OD1zMD62PUBvVQ>?	NGHG[VJUSU6JRWK=
ES8	M4\ldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvHZXU1UUN3ME2xNE46KG6P	M{HOWHNCVkeHUh?=
PA-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rLUWlEPTB;MUGuPFIhdk1?	MkXsV2FPT0WU
Mewo	NULFdXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPRZo5KSzVyPUGxMlk6KG6P	MmnnV2FPT0WU
HSC-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVT0SIRFUUN3ME2xNk4zOSCwTR?=	NF7sZmdUSU6JRWK=
H4	NGnHRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTF{Lk[3JI5O	NV3WW2h4W0GQR1XS
BB65-RCC	M3vnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfWXYxKSzVyPUGyMlczKG6P	NHj1RpNUSU6JRWK=
NCI-H1793	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfPTHlKSzVyPUGyMlgzKG6P	NYfCb5BpW0GQR1XS
KARPAS-45	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLib4ZKSzVyPUGzMlUyKG6P	NUjGd21xW0GQR1XS
GCT	M2rYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ezNGlEPTB;MUOuOlghdk1?	NYL6coxIW0GQR1XS
EoL-1	NIfoeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF\|LkmzJI5O	NUj5UVU1W0GQR1XS
LB2241-RCC	NWDv[29PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF2LkCxJI5O	MnLWV2FPT0WU
ES5	NWrCWW55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTF2Lke0JI5O	M3nIeXNCVkeHUh?=
LOXIMVI	NV\EfpVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF2Lkm5JI5O	M3PpfHNCVkeHUh?=
COR-L105	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjodJJDUUN3ME2xOU4xPCCwTR?=	MUnTRW5ITVJ?
P12-ICHIKAWA	M{LFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTF3LkGgcm0>	M1fZ[3NCVkeHUh?=
CHL-1	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnoTWM2OD1zNT60OUBvVQ>?	NInpXWpUSU6JRWK=
VMRC-RCZ	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1i3U2lEPTB;MUWuOlMhdk1?	NXzEOWlyW0GQR1XS
HH	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\VPFA{UUN3ME2xOU44KG6P	NF;COFZUSU6JRWK=
NUGC-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzG[\|lKSzVyPUG2MlM1KG6P	MV7TRW5ITVJ?
EGI-1	NV;2OpZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYexO3BuUUN3ME2xOk41OyCwTR?=	NUDZXlhlW0GQR1XS
OS-RC-2	M4\GRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF4LkS3JI5O	M{\zS3NCVkeHUh?=
MOLT-16	NUPtXGtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGflRohKSzVyPUG3MlE2KG6P	NFH1VZBUSU6JRWK=
NCI-H209	M2HXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF5LkK5JI5O	Mnq1V2FPT0WU
697	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzG[mlKSzVyPUG3MlQ{KG6P	Ml3sV2FPT0WU
D-56MG	MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF5Lk[5JI5O	NGfRNoRUSU6JRWK=
VA-ES-BJ	NV3P[mkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{f3XmlEPTB;MUeuPFMhdk1?	MlfFV2FPT0WU
EW-16	NHHhWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T4ZmlEPTB;MUiuNFQhdk1?	MoGxV2FPT0WU
HGC-27	NWC4[G1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHZWGdKSzVyPUG4MlA3KG6P	NVXIXWtMW0GQR1XS
ES7	NHrJUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HPSWlEPTB;MUiuNFkhdk1?	NXvvTHJUW0GQR1XS
HuH-7	NF\ibIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHZSoFoUUN3ME2xPE41KG6P	MmTBV2FPT0WU
BCPAP	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjjTWM2OD1zOD62OUBvVQ>?	MXvTRW5ITVJ?
SW1710	NILGbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\pTWM2OD1zOD63NkBvVQ>?	M{PBeXNCVkeHUh?=
IST-MEL1	NU[5cmc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnZ[JV4UUN3ME2xPE44PyCwTR?=	M3rYfHNCVkeHUh?=
SF295	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF6LkmzJI5O	NVvRbmtkW0GQR1XS
RPMI-7951	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITEUphKSzVyPUG5MlI5KG6P	NXTLNFZRW0GQR1XS
SF126	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrWTWM2OD1zOT60NUBvVQ>?	M1HwUHNCVkeHUh?=
GAMG	NXX4VmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrYc4tKSzVyPUG5MlQ5KG6P	NXqxXo5qW0GQR1XS
KNS-81-FD	NGrW[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTaUHFoUUN3ME2xPU42PCCwTR?=	NUPLNJZJW0GQR1XS
RT-112	Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLWTWM2OD1zOT62OkBvVQ>?	NVz4b5JsW0GQR1XS
DEL	NInQOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJyLkS5JI5O	NH3zNmtUSU6JRWK=
CGTH-W-1	M3XiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\s[4xnUUN3ME2yNE43OyCwTR?=	NXXKWIlLW0GQR1XS
HOS	NVnqPG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7lcnZKSzVyPUKxMlA3KG6P	NWOyXXUxW0GQR1XS
ES4	NUj3bVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrXeIhKSzVyPUKxMlA5KG6P	NWH6VY9xW0GQR1XS
RXF393	M2rTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PTOmlEPTB;MkGuOFUhdk1?	Mnm0V2FPT0WU
NCI-H2030	M13sVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O4NWlEPTB;MkGuOVIhdk1?	NUX5dVlzW0GQR1XS
YH-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHNdZdKSzVyPUKxMlg5KG6P	MULTRW5ITVJ?
HT-1080	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PSfmlEPTB;MkGuPVMhdk1?	NYXvUHBFW0GQR1XS
NCI-SNU-1	NH\CWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIf2fHJKSzVyPUKxMlk2KG6P	MWHTRW5ITVJ?
G-402	NH\wZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWixTlBKUUN3ME2yNk4yPiCwTR?=	NEe0TGNUSU6JRWK=
786-0	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe3c2dKSzVyPUKyMlI6KG6P	MU\TRW5ITVJ?
ME-180	NIHNZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW0bJJKSzVyPUKyMlQ{KG6P	NEK5SodUSU6JRWK=
NB69	NEfzbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnsTWM2OD1{Mj61N{BvVQ>?	NFvV[oNUSU6JRWK=
J-RT3-T3-5	NV;FTYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\wOo1KSzVyPUKyMlk3KG6P	NVrGR4VFW0GQR1XS
TGBC1TKB	NXq4eHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3FSWlYUUN3ME2yN{4xPSCwTR?=	Mo\4V2FPT0WU
SW780	NHP3OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTFWnU2UUN3ME2yN{4yOyCwTR?=	NFXjeZlUSU6JRWK=
MG-63	M{HMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnaT2RtUUN3ME2yN{41PSCwTR?=	NW\wUYh{W0GQR1XS
BV-173	NEDTc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXuTWM2OD1{Mz64O{BvVQ>?	NIDONmFUSU6JRWK=
CAL-51	NF7QR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorxTWM2OD1{Mz64PUBvVQ>?	NV\1OlZLW0GQR1XS
A375	M{KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJ\|LkmzJI5O	MWPTRW5ITVJ?
MEL-HO	NFvHWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TSSGlEPTB;MkSuNFQhdk1?	MXvTRW5ITVJ?
EFO-27	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPxSFlKSzVyPUK0MlM{KG6P	NYm0N2pUW0GQR1XS
Hs-578-T	NV\iT5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ2LkW4JI5O	NH\iSXVUSU6JRWK=
NBsusSR	NFnZWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnj0TWM2OD1{ND62JI5O	Mny0V2FPT0WU
CTB-1	NUnJUlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLFTWM2OD1{ND62O{BvVQ>?	NHi3XVJUSU6JRWK=
FTC-133	NGHXPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XvdmlEPTB;MkWuNUBvVQ>?	MYDTRW5ITVJ?
MOLT-4	NWrofZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnWWIpKSzVyPUK1MlEzKG6P	NFTIdG9USU6JRWK=
HO-1-N-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TWcGlEPTB;MkWuNVUhdk1?	MmHDV2FPT0WU
ES3	M4ri[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnT[FZKSzVyPUK1MlIzKG6P	MnrlV2FPT0WU
TI-73	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfOTWM2OD1{NT6yPEBvVQ>?	MYfTRW5ITVJ?
MPP-89	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoeyTWM2OD1{NT6zNkBvVQ>?	NFLFSIVUSU6JRWK=
KYSE-150	NXTZV5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{X0Z2lEPTB;MkWuPFkhdk1?	NInOcppUSU6JRWK=
LXF-289	NUDIeGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDGRmlKSzVyPUK2MlA1KG6P	NFHTWWpUSU6JRWK=
SK-LU-1	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDCVW9KSzVyPUK2MlE4KG6P	M{HmdHNCVkeHUh?=
HOP-92	NFS2OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIq5TYZKSzVyPUK2MlQ5KG6P	NF;peZNUSU6JRWK=
HuO9	NVjSU\|lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHUNZdKSzVyPUK2Mlc3KG6P	NVO5VWR[W0GQR1XS
SW962	NF6xTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJ4Lke2JI5O	M4\4b3NCVkeHUh?=
RS4-11	M1TjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnXO4RxUUN3ME2yOk46OSCwTR?=	NYLFT2N{W0GQR1XS
NCI-H292	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJ5IH7N	MWXTRW5ITVJ?
DB	NXXWcZFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn2TWM2OD1{Nz6zOkBvVQ>?	M1nTR3NCVkeHUh?=
SW1088	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\YTWM2OD1{OD6yPUBvVQ>?	NVHiXHRsW0GQR1XS
A204	NITlNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXaRXJKSzVyPUK4MlQ4KG6P	MYPTRW5ITVJ?
A3-KAW	M4X2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;jbmlEPTB;MkiuOlQhdk1?	NUPQOlBnW0GQR1XS
MV-4-11	M4iyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJ6Lkegcm0>	NVjrenhoW0GQR1XS
ES1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLIR4lKSzVyPUK4Mlg1KG6P	MXPTRW5ITVJ?
ONS-76	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH3W2dzUUN3ME2yPU4xPSCwTR?=	M3HpbHNCVkeHUh?=
D-263MG	NWPhOoxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fLfmlEPTB;MkmuN\|Uhdk1?	NFzjSlhUSU6JRWK=
U-2-OS	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvLTWM2OD1{OT61JI5O	NFe1[oNUSU6JRWK=
T98G	M{fyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHyOpI3UUN3ME2yPU45QCCwTR?=	MojGV2FPT0WU
GI-ME-N	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTJ7LkmxJI5O	NUXHN4R{W0GQR1XS
BHT-101	M1vLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;FTWM2OD1\|MD6wOUBvVQ>?	MUjTRW5ITVJ?
NOS-1	NF;mT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTNyLkGyJI5O	NX7ifoFkW0GQR1XS
AsPC-1	NH[0bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnJTWM2OD1\|MD6yJI5O	MkLXV2FPT0WU
QIMR-WIL	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TTWWlEPTB;M{CuOkBvVQ>?	M3z6PHNCVkeHUh?=
JVM-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv0TWM2OD1\|MD64N{BvVQ>?	MWHTRW5ITVJ?
KU-19-19	NF;WPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHpR4RsUUN3ME2zNU4yOyCwTR?=	NFfCVIJUSU6JRWK=
OVCAR-8	NEfJOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTNzLkK2JI5O	MXHTRW5ITVJ?
BEN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\SSGlEPTB;M{GuOlMhdk1?	NUjuc29qW0GQR1XS
BE-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXnTWM2OD1\|MT64NkBvVQ>?	MWPTRW5ITVJ?
EW-18	M3rWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnHd41KSzVyPUOxMlg3KG6P	M1nIfHNCVkeHUh?=
ECC10	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\FVWpLUUN3ME2zNU46PSCwTR?=	Mo[3V2FPT0WU
CTV-1	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXXNVVPUUN3ME2zNk45OiCwTR?=	MV\TRW5ITVJ?
COLO-800	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTN{LkmyJI5O	MWHTRW5ITVJ?
A2058	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXKTFNKSzVyPUOzMlI2KG6P	MlvwV2FPT0WU
VM-CUB-1	NV3ibpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjM[JBsUUN3ME2zN{41OyCwTR?=	MUTTRW5ITVJ?
Ca9-22	MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXycpY2UUN3ME2zN{42PSCwTR?=	Ml7DV2FPT0WU
COLO-684	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnQRWpKSzVyPUOzMlU5KG6P	MkPZV2FPT0WU
RPMI-8226	M3rDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnP1TWM2OD1\|Mz64NkBvVQ>?	MmPiV2FPT0WU
SK-NEP-1	M2LnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTN2LkG1JI5O	M{LCT3NCVkeHUh?=
Becker	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\pXZhKSzVyPUO0MlIyKG6P	MkLIV2FPT0WU
NCI-H28	M2XGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jsfGlEPTB;M{SuOFQhdk1?	M1K1W3NCVkeHUh?=
CAL-120	NXPoeFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTN2LkeyJI5O	NXW1cZY{W0GQR1XS
MDA-MB-157	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkixTWM2OD1\|NT60NUBvVQ>?	M2rjVnNCVkeHUh?=
OVCAR-5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jrZmlEPTB;M{WuOFchdk1?	NX3sVnlSW0GQR1XS
LAMA-84	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTN3Lki3JI5O	NVjSSmpMW0GQR1XS
CAKI-1	M1PZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoX0TWM2OD1\|Nj60N{BvVQ>?	MX;TRW5ITVJ?
Daoy	NFm3WVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3CZ4xKSzVyPUO2Mlchdk1?	M{XEWHNCVkeHUh?=
CAL-62	M{\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{myemlEPTB;M{[uPFYhdk1?	MlXZV2FPT0WU
8-MG-BA	M3H6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HQOmlEPTB;M{euNlUhdk1?	NFLPfIZUSU6JRWK=
8505C	M{POOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPlO4tKSzVyPUO3MlUyKG6P	NY\kO3hsW0GQR1XS
LNCaP-Clone-FGC	M2Ty[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;xe2lEPTB;M{euOVkhdk1?	NGXzN4pUSU6JRWK=
CAL-39	NWL0TYpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTN5Lkmgcm0>	NXHtUYZ3W0GQR1XS
MN-60	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPlTWM2OD1\|Nz65OkBvVQ>?	NIH4WnJUSU6JRWK=
RKO	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDQUXJbUUN3ME2zPE4{OyCwTR?=	MnXSV2FPT0WU
U251	NFHWe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrQO\|V5UUN3ME2zPE41OyCwTR?=	M4\SV3NCVkeHUh?=
SJSA-1	MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrwdZV5UUN3ME2zPE42PCCwTR?=	MVrTRW5ITVJ?
CAL-12T	NUHpVVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPYWmFKSzVyPUO4MlYhdk1?	M2n3THNCVkeHUh?=
HCC1419	M1nYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXNcVlLUUN3ME2zPE44OSCwTR?=	MXPTRW5ITVJ?
CO-314	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvoc3JKSzVyPUO4Mlc1KG6P	MofjV2FPT0WU
LB1047-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzGSYVKSzVyPUO4MlgyKG6P	NYnjcXhKW0GQR1XS
A101D	NH7Ie2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWi3N49LUUN3ME2zPE46PyCwTR?=	M3PiWXNCVkeHUh?=
MDA-MB-175-VII	M1XHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTN7LkWxJI5O	MWjTRW5ITVJ?
MZ2-MEL	NVHJTo02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTN7Lk[2JI5O	NFjvfZpUSU6JRWK=
NB5	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHqT\|lOUUN3ME20NE43PCCwTR?=	MkHoV2FPT0WU
G-401	M2HSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrpZ5pKSzVyPUSwMlgzKG6P	MnzUV2FPT0WU
HT	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XNe2lEPTB;NEGuNFIhdk1?	M2K0OnNCVkeHUh?=
8305C	M{Pl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;1OmlEPTB;NEGuPFchdk1?	NX7ad2ZuW0GQR1XS
BHY	NGK4UWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTR{LkeyJI5O	MV7TRW5ITVJ?
NTERA-S-cl-D1	NFSwVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrMcHV1UUN3ME20N{BvVQ>?	M1PGPXNCVkeHUh?=
T-24	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrITWM2OD12Mz64N{BvVQ>?	MXfTRW5ITVJ?
EPLC-272H	M{O2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfkZYdKSzVyPUS0MlM6KG6P	M2XJZ3NCVkeHUh?=
PSN1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfRO2NKSzVyPUS0MlQhdk1?	M1X6VnNCVkeHUh?=
NCI-H2452	NVr1S5NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTR2LkW4JI5O	M1K5fXNCVkeHUh?=
KS-1	NET3SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTR2Lk[2JI5O	M1XiS3NCVkeHUh?=
HD-MY-Z	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTR2LkmyJI5O	M4rPbXNCVkeHUh?=
KNS-62	NFPiUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2qybmlEPTB;NEWuN\|ghdk1?	MmPIV2FPT0WU
NOMO-1	NYrORpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fUNmlEPTB;NEWuPFchdk1?	NYXCTHZ5W0GQR1XS
SK-HEP-1	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITNOIdKSzVyPUS2MlA1KG6P	M2L6XnNCVkeHUh?=
IGR-1	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nSUmlEPTB;NE[uNVMhdk1?	NWLyN\|R{W0GQR1XS
KYSE-180	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzqSldDUUN3ME20Ok4yPyCwTR?=	NUHrc2RrW0GQR1XS
EW-22	M4HLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLqeplKSzVyPUS2MlIhdk1?	NXzBXHJyW0GQR1XS
NCI-H1355	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17oNmlEPTB;NE[uN\|Qhdk1?	MkfxV2FPT0WU
DOHH-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnqTWM2OD12Nj6zO{BvVQ>?	NE\UOHJUSU6JRWK=
A4-Fuk	NIrnXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjoSXdvUUN3ME20Ok42OiCwTR?=	MkO2V2FPT0WU
PC-14	M3P0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\EUY12UUN3ME20Ok42PyCwTR?=	MVjTRW5ITVJ?
TE-5	NHOyS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfaW\|JVUUN3ME20Ok45PCCwTR?=	MlTmV2FPT0WU
LB996-RCC	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\FWVlRUUN3ME20O{4yQSCwTR?=	Ml31V2FPT0WU
NCI-H1623	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:2TWM2OD12Nz63OkBvVQ>?	MlfrV2FPT0WU
NCI-H1155	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP6c5BXUUN3ME20PE4{OiCwTR?=	MkmyV2FPT0WU
LoVo	NUXpbldHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TM[GlEPTB;NEiuOEBvVQ>?	M2DvZ3NCVkeHUh?=
MCF7	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTR6LkW4JI5O	MnHkV2FPT0WU
AGS	NIjNSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TMemlEPTB;NEiuO\|chdk1?	NELkeXlUSU6JRWK=
PFSK-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrSdXVKSzVyPUS5MlA3KG6P	NG\qdHFUSU6JRWK=
22RV1	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmK5TWM2OD12OT6wPUBvVQ>?	NFvteXNUSU6JRWK=
COR-L23	NUP6SGN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2SzZmlEPTB;NEmuNVYhdk1?	NHHQRmJUSU6JRWK=
D-283MED	M13vNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTR7Lk[xJI5O	NVnrepdCW0GQR1XS
SW982	NXO2PGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTQTWM2OD12OT65NUBvVQ>?	MnKyV2FPT0WU
SW620	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTVyLkO2JI5O	NFPWcYdUSU6JRWK=
KYSE-140	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jLO2lEPTB;NUCuOVUhdk1?	NGHmO2pUSU6JRWK=
GCIY	M3fTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTpdmYxUUN3ME21NE43PyCwTR?=	Mk\xV2FPT0WU
MHH-ESS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PRSGlEPTB;NUGuPVUhdk1?	M4\jbnNCVkeHUh?=
D-423MG	M1rLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTYTWM2OD13Mj6wPEBvVQ>?	M3S0dXNCVkeHUh?=
SF539	NVi3Zox3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjUZoJ6UUN3ME21Nk4{PSCwTR?=	NVrPSoJ6W0GQR1XS
RPMI-2650	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITL[ZZKSzVyPUWyMlY6KG6P	NIm2d2NUSU6JRWK=
GR-ST	NGHGZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TybGlEPTB;NUKuPFchdk1?	M{DNN3NCVkeHUh?=
YKG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf0TphsUUN3ME21N{BvVQ>?	MYHTRW5ITVJ?
SK-MES-1	M3ftNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHezOpJKSzVyPUWzMlI3KG6P	NFXHdI5USU6JRWK=
HLE	NYniOocyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;hRmlEPTB;NUOuOFchdk1?	MmfXV2FPT0WU
RVH-421	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTV\|Lk[3JI5O	NFyxcZlUSU6JRWK=
C32	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvWTWM2OD13Mz64N{BvVQ>?	MWXTRW5ITVJ?
GB-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjE[GN[UUN3ME21OE4zKG6P	MW\TRW5ITVJ?
SNB75	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe4TWM2OD13ND6yOkBvVQ>?	M3LLR3NCVkeHUh?=
EM-2	NGK2fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPzPGw5UUN3ME21OE41KG6P	MXnTRW5ITVJ?
RH-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;vc2lEPTB;NUSuO{BvVQ>?	MmHhV2FPT0WU
NKM-1	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7DfYFKSzVyPUW0MlgyKG6P	NE[yeVlUSU6JRWK=
NCI-H2405	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDOZZVHUUN3ME21OE45QCCwTR?=	MVHTRW5ITVJ?
KYSE-450	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XjSWlEPTB;NUWuNVYhdk1?	M{P5UnNCVkeHUh?=
A704	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFThPHhKSzVyPUW1MlU6KG6P	MmHnV2FPT0WU
HAL-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTV3LkizJI5O	NHfyZ25USU6JRWK=
TE-11	NW\kOpg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTV3Lkm5JI5O	NVLkV492W0GQR1XS
DOK	NGLD[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjOXXVKSzVyPUW2MlAzKG6P	NGTKTI5USU6JRWK=
KY821	NH:3O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrlTWM2OD13Nj6yJI5O	NX:3O5B2W0GQR1XS
KGN	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTnTWM2OD13Nj6zNkBvVQ>?	MoexV2FPT0WU
MC116	MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zuPWlEPTB;NUeuPEBvVQ>?	NXXwdm9[W0GQR1XS
PANC-08-13	NHWyXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPY[2FWUUN3ME21PE4xOSCwTR?=	MU\TRW5ITVJ?
KE-37	NUjpb45oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnH4TWM2OD13OD63O{BvVQ>?	MV\TRW5ITVJ?
KYSE-410	MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTV7LkS3JI5O	Mk\oV2FPT0WU
RO82-W-1	NUfQXnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTV7Lkmgcm0>	NX71eFVXW0GQR1XS
M14	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTZyLkC0JI5O	NFLaS\|VUSU6JRWK=
GI-1	NUnUWnFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DqR2lEPTB;NkCuN{BvVQ>?	NXexNmk3W0GQR1XS
ML-2	M{jk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH1TWM2OD14MD62NkBvVQ>?	NIDJ[ZhUSU6JRWK=
BFTC-905	NFjYT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXoTYtKSzVyPU[wMlY2KG6P	NGe2U5FUSU6JRWK=
DMS-273	NHy0blBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jBXmlEPTB;NkCuPFchdk1?	MXjTRW5ITVJ?
MDA-MB-361	M{L6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTZzIH7N	NY\RW\|dpW0GQR1XS
MSTO-211H	M4PtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHYTWM2OD14Mz61NUBvVQ>?	NFz0V2FUSU6JRWK=
MEG-01	NYf6eZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlK1TWM2OD14Mz61NkBvVQ>?	MWXTRW5ITVJ?
M059J	M4LpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfsfHpKSzVyPU[zMlU5KG6P	MWDTRW5ITVJ?
LN-405	NHzEbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\0VGlEPTB;NkOuPFUhdk1?	M4rPTnNCVkeHUh?=
NCI-H1581	NHOxXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHYfIFVUUN3ME22OE4xOyCwTR?=	MWrTRW5ITVJ?
TCCSUP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPqdWVkUUN3ME22OE42OyCwTR?=	MXHTRW5ITVJ?
SW872	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PqV2lEPTB;NkSuOVchdk1?	M2PLNHNCVkeHUh?=
KYSE-510	NV\5WYtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljrTWM2OD14NT63OUBvVQ>?	Mm[4V2FPT0WU
NCI-H1792	NHnMZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYOwbYhPUUN3ME22Ok4yPSCwTR?=	M2ThU3NCVkeHUh?=
SW13	NF70R2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTZ4LkWgcm0>	MljyV2FPT0WU
TE-8	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn1T3BKSzVyPU[2MlUzKG6P	MoC3V2FPT0WU
SCH	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTZ5LkGgcm0>	NED3NYNUSU6JRWK=
NEC8	NEjOU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHQbWt2UUN3ME22O{4zPCCwTR?=	M1u1bXNCVkeHUh?=
HuO-3N1	M1rMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXL[\|NzUUN3ME22O{4{OSCwTR?=	NUHiZ5JPW0GQR1XS
EFM-19	NXfze\|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rx[2lEPTB;NkeuOUBvVQ>?	MXHTRW5ITVJ?
HEC-1	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz3OottUUN3ME22O{42OiCwTR?=	MYnTRW5ITVJ?
T47D	M2HPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTZ5Lki3JI5O	NYDZeGlOW0GQR1XS
SNU-423	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTZ5Lkm4JI5O	NIHJS4xUSU6JRWK=
WM-115	M17JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz5Z3NMUUN3ME22PE4yPCCwTR?=	NXixbJNPW0GQR1XS
CaR-1	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUOwVYJlUUN3ME22PE4zPSCwTR?=	M3vGR3NCVkeHUh?=
KU812	M3yyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHOSllKSzVyPU[4MlY6KG6P	MmPnV2FPT0WU
AM-38	NEC2WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS5TWM2OD14OT6zNUBvVQ>?	MXvTRW5ITVJ?
KOSC-2	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfreIZsUUN3ME22PU46PyCwTR?=	MWTTRW5ITVJ?
MC-IXC	NGLRVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vUSGlEPTB;N{CuNFghdk1?	MlnKV2FPT0WU
SCC-4	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;YZpRGUUN3ME23NU4{QCCwTR?=	MVjTRW5ITVJ?
Calu-3	M2\5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn6dlNKSzVyPUexMlk5KG6P	M3TNVHNCVkeHUh?=
RPMI-8866	NFS5OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fmSmlEPTB;N{KuPFIhdk1?	M2[5cnNCVkeHUh?=
OVCAR-4	NGr3UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTd\|LkO2JI5O	MWDTRW5ITVJ?
OAW-42	M3T2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;rd\|FKSzVyPUezMlM6KG6P	MnXOV2FPT0WU
ATN-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;oWmlEPTB;N{OuPFchdk1?	MXHTRW5ITVJ?
CHP-212	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nabWlEPTB;N{SuPVUhdk1?	MVjTRW5ITVJ?
C2BBe1	NFXDTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHVc\|hSUUN3ME23OU4xOyCwTR?=	MW\TRW5ITVJ?
A498	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;Wd3JKSzVyPUe1MlE2KG6P	NYD0XnZNW0GQR1XS
SH-4	NFjnPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF23XnFKSzVyPUe1MlIyKG6P	NISyXWVUSU6JRWK=
SNU-449	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PiWGlEPTB;N{WuO\|khdk1?	M1nacnNCVkeHUh?=
RD	Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV25R5JXUUN3ME23OU45PiCwTR?=	NGjlXI5USU6JRWK=
PANC-03-27	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPXT25KSzVyPUe2MlI2KG6P	NGnicWVUSU6JRWK=
S-117	NXTOS5FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTd4LkK3JI5O	M2\BS3NCVkeHUh?=
SK-MEL-2	NFzlTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfEWWNKSzVyPUe2Mlc2KG6P	MXXTRW5ITVJ?
LK-2	NGjBOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfBVGJKSzVyPUe3MlA2KG6P	M2nzO3NCVkeHUh?=
CP50-MEL-B	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X3fmlEPTB;N{euOEBvVQ>?	M1HrUnNCVkeHUh?=
647-V	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\ZVmlEPTB;N{iuNFchdk1?	MmHIV2FPT0WU
LU-134-A	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYflbHVJUUN3ME23PU4xOyCwTR?=	M36yTXNCVkeHUh?=
5637	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XX[mlEPTB;N{muNlMhdk1?	M1;FPHNCVkeHUh?=
NCI-H1437	M4\sNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzhdGptUUN3ME24NE42KG6P	NH\WN4xUSU6JRWK=
NCI-H460	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXkTWM2OD16MT6yN{BvVQ>?	M2HmZXNCVkeHUh?=
BxPC-3	M3rRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnKOodKSzVyPUixMlQ3KG6P	M4P2PXNCVkeHUh?=
CAN	NFXXd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjWTWM2OD16MT64OEBvVQ>?	NYW4eZRFW0GQR1XS
KINGS-1	NEPNNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTh{LkOyJI5O	NUfFfnp7W0GQR1XS
OCUB-M	NX;SUXdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjQdlV5UUN3ME24Nk41OSCwTR?=	M2HrbHNCVkeHUh?=
KALS-1	NELzWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTh{LkW0JI5O	Ml71V2FPT0WU
OCI-AML2	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUP5VHVsUUN3ME24Nk43OSCwTR?=	M4nEbXNCVkeHUh?=
A253	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorrTWM2OD16Mj62OUBvVQ>?	NY\5WJhjW0GQR1XS
LCLC-97TM1	NELwNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT4[FlKSzVyPUiyMlg3KG6P	M2\YcXNCVkeHUh?=
NCI-H520	M{DkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;6TWM2OD16Mz6wOkBvVQ>?	NVHJfHRnW0GQR1XS
P30-OHK	NV;UPFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnNd3dGUUN3ME24N{42KG6P	M3rxenNCVkeHUh?=
SBC-5	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTh\|LkWyJI5O	NHrydmlUSU6JRWK=
HCE-T	NIT2WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzWTWM2OD16Mz63OEBvVQ>?	MWXTRW5ITVJ?
JEG-3	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17hW2lEPTB;OESuNUBvVQ>?	NVfXdphPW0GQR1XS
KG-1	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nVRWlEPTB;OESuNlQhdk1?	Mnf3V2FPT0WU
MIA-PaCa-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonhTWM2OD16ND61OEBvVQ>?	MlXVV2FPT0WU
CAL-33	NYn6TGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XYc2lEPTB;OEWuNFghdk1?	M3rj[nNCVkeHUh?=
639-V	M4PXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;acnhKSzVyPUi1MlQzKG6P	NXrxSWdPW0GQR1XS
NCI-H1048	NUfVUJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTMTWM2OD16Nj6zNUBvVQ>?	NV;sVVg1W0GQR1XS
NCI-H1573	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz1OoxlUUN3ME24O{41QCCwTR?=	NIrsZ2NUSU6JRWK=
NCI-H2228	M2nRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzEUGV7UUN3ME24PE4zPiCwTR?=	MYHTRW5ITVJ?
NB14	M3PCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWezRYdwUUN3ME24PE4{KG6P	NIXqVmhUSU6JRWK=
SCC-25	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HPN2lEPTB;OEmuPFIhdk1?	NH;TempUSU6JRWK=
A431	NYruW2Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;xd4tKSzVyPUi5Mlk4KG6P	MmS1V2FPT0WU
SN12C	MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ntc2lEPTB;OUCuOlIhdk1?	M{TkcXNCVkeHUh?=
HuCCT1	NHvOS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXT0SIdLUUN3ME25NE44PiCwTR?=	NY\DSItxW0GQR1XS
LS-123	NIPjWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3xOWdZUUN3ME25Nk4yQCCwTR?=	NYHYXI8xW0GQR1XS
CAL-85-1	M3L2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHITWM2OD17Mj60PEBvVQ>?	NIX5ZlRUSU6JRWK=
ES6	NVz5dGloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzvO3k4UUN3ME25Nk45OyCwTR?=	M3P5WHNCVkeHUh?=
NCI-H650	NFPTblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzBZ\|VKSzVyPUm0MlA6KG6P	MluxV2FPT0WU
NCI-H446	NF\ldpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnWTWM2OD17NT6xNkBvVQ>?	NF;SPWRUSU6JRWK=
EW-13	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPBTWM2OD17NT63OUBvVQ>?	M3H1eHNCVkeHUh?=
HSC-2	NG\PPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7QPXdSUUN3ME25OU45QSCwTR?=	NUX1TWVzW0GQR1XS
U031	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTl4LkezJI5O	MkDDV2FPT0WU
EW-11	M3y5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTl4Lki4JI5O	NVTsVY97W0GQR1XS
GAK	NHP0SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfxS3BoUUN3ME25PE46OyCwTR?=	Mnf4V2FPT0WU
SK-OV-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC0TWM2OD1zMECuNFchdk1?	NFz2NYxUSU6JRWK=
OMC-1	NEHVUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHzPGRKSzVyPUGwNE4yQCCwTR?=	NFHFN3JUSU6JRWK=
TK10	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnv[3VKSzVyPUGwNE4zOSCwTR?=	NYrwR3lxW0GQR1XS
EKVX	M2X1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIe0PWpKSzVyPUGwNE43KG6P	MkLRV2FPT0WU
Detroit562	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu3VGEyUUN3ME2xNFIvOTdibl2=	MnTpV2FPT0WU
SF268	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTFTWM2OD1zMEKuN\|Qhdk1?	NHXMfWRUSU6JRWK=
SNU-387	M{DDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPsTWM2OD1zMESuNVchdk1?	NUn1Z2ZMW0GQR1XS
MDA-MB-231	NGfzbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nXfWlEPTB;MUC1MlA3KG6P	M1ro[nNCVkeHUh?=
NCI-H1563	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[wdW1KSzVyPUGwOU4yQCCwTR?=	MknGV2FPT0WU
D-502MG	M3fod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;l[29KSzVyPUGwOU44KG6P	NIXGbHBUSU6JRWK=
A2780	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFyNj60O{BvVQ>?	MXfTRW5ITVJ?
IA-LM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;wTWM2OD1zMEeuOVEhdk1?	M{HVRnNCVkeHUh?=
D-392MG	M1PlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn30TWM2OD1zMEeuOVQhdk1?	NWTIXJM3W0GQR1XS
MS-1	NYW1eXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXpSII{UUN3ME2xNFcvPzFibl2=	MX;TRW5ITVJ?
SW1990	NGnKOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O0cmlEPTB;MUC4MlU1KG6P	MmHlV2FPT0WU
HEL	NEDrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPDTWM2OD1zMEmuNlkhdk1?	MYHTRW5ITVJ?
SW1573	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTFyOT6zNUBvVQ>?	Mn\MV2FPT0WU
SW1783	NUDXfnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fheWlEPTB;MUGwMlIzKG6P	NEDP[WRUSU6JRWK=
COLO-680N	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTFzMD63OkBvVQ>?	MV7TRW5ITVJ?
NCI-N87	M1TjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFzMT6wOEBvVQ>?	MofjV2FPT0WU
SK-MEL-28	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7sS4hKSzVyPUGxNU42PSCwTR?=	NHLhOpNUSU6JRWK=
BT-20	NIP5TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfrTWM2OD1zMUKuNFEhdk1?	Ml3aV2FPT0WU
NCI-H1648	M2DNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nzd2lEPTB;MUGzJI5O	M4jLNXNCVkeHUh?=
no-11	NF\NUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1W0NmlEPTB;MUGzMlI5KG6P	NULrNoZ[W0GQR1XS
MOLT-13	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjrZWVKSzVyPUGxN{41PCCwTR?=	M2nFU3NCVkeHUh?=
NCI-H2170	M3LvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkewTWM2OD1zMUSuOVEhdk1?	M4fM[nNCVkeHUh?=
HTC-C3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HaNmlEPTB;MUG2Mlg2KG6P	Ml;wV2FPT0WU
LU-99A	M4D5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTFzNz6yNUBvVQ>?	M3HLNnNCVkeHUh?=
HCC2998	M2PU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj6SWNXUUN3ME2xNVcvQTJibl2=	NGPjb5lUSU6JRWK=
NB13	Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7RTWM2OD1zMUeuPVkhdk1?	M1vvPXNCVkeHUh?=
GT3TKB	NVvweHdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrBd49KSzVyPUGxPE4xQCCwTR?=	NHGxe4pUSU6JRWK=
BT-549	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoWzTWM2OD1zMUiuPVUhdk1?	M1\EZXNCVkeHUh?=
NCI-H747	NULOb3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXNZZNYUUN3ME2xNVkvOzRibl2=	MXXTRW5ITVJ?
EW-1	NF7vfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTF{MD6yJI5O	NHPEVXRUSU6JRWK=
LB831-BLC	NXPaeJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PwXmlEPTB;MUKwMlY{KG6P	MV7TRW5ITVJ?
NMC-G1	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfwTWM2OD1zMkGuNVEhdk1?	M2fC[nNCVkeHUh?=
COLO-679	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HMO2lEPTB;MUKyMlE2KG6P	NUL6dnJbW0GQR1XS
HL-60	M2nwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLoTWM2OD1zMkOuNUBvVQ>?	NHewbI5USU6JRWK=
MKN7	NXL0PWVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnYTWM2OD1zMkOuPFMhdk1?	NWPWOJZJW0GQR1XS
RERF-LC-MS	NIHNZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHlV2RKSzVyPUGyOE4{OSCwTR?=	NYnlS25lW0GQR1XS
DMS-114	M2jRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELEd4xKSzVyPUGyOU4xQSCwTR?=	MonCV2FPT0WU
HuP-T4	M2Lu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTF{Nj65O{BvVQ>?	MVPTRW5ITVJ?
HCC2157	NXnWNlNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DS[GlEPTB;MUK3MlUhdk1?	MUfTRW5ITVJ?
SKG-IIIa	NFPLXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfVTWM2OD1zMkiuPEBvVQ>?	M13FV3NCVkeHUh?=
HCT-116	M{HRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX0R2NKSzVyPUGzNE43PCCwTR?=	M363Z3NCVkeHUh?=
BB30-HNC	NEHEeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\MTWM2OD1zM{CuO\|ghdk1?	MYDTRW5ITVJ?
KYSE-270	NIjyTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\lT3RKUUN3ME2xN\|AvQDhibl2=	NVLXfGk6W0GQR1XS
MFM-223	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\RO4VKSzVyPUGzNU42OSCwTR?=	NIjabZJUSU6JRWK=
NH-12	M3K4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4npSWlEPTB;MUOyMlk6KG6P	M1LifHNCVkeHUh?=
U-118-MG	NGjWc\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ftPWlEPTB;MUOzMlYzKG6P	MWXTRW5ITVJ?
ESS-1	NV3OPIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[yTWM2OD1zM{WuNVghdk1?	NWnuXHBFW0GQR1XS
D-247MG	NIftfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fmUWlEPTB;MUO1MlIyKG6P	MoDhV2FPT0WU
IGROV-1	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjNZnNKSzVyPUGzOU44PiCwTR?=	NWnYd4R1W0GQR1XS
C-33-A	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvsTWM2OD1zM{WuPVchdk1?	MljsV2FPT0WU
NCI-H1693	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TBfmlEPTB;MUO2MlEzKG6P	NYnKSWxLW0GQR1XS
MLMA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTF\|Nj61PEBvVQ>?	NVfIbWI2W0GQR1XS
SK-N-AS	NWXr[Hk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTiTWM2OD1zM{euNVchdk1?	NFnz[2VUSU6JRWK=
NCI-H1755	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHH2NXNKSzVyPUGzPE45PSCwTR?=	NYfRWnJ3W0GQR1XS
CHP-134	M{\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvTNlZKSzVyPUGzPU42PSCwTR?=	MX7TRW5ITVJ?
LS-513	M{PRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vPdGlEPTB;MUSwMlkyKHCP	M3\0OXNCVkeHUh?=
TE-12	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjmVZhKSzVyPUG0NE46OyCwTR?=	M37hNHNCVkeHUh?=
KNS-42	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF2ND6zJI5O	M1jRUXNCVkeHUh?=
SJRH30	NF7VOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LLWmlEPTB;MUS0MlQ1KG6P	MmTwV2FPT0WU
NCI-H1092	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIflOZBKSzVyPUG0OE42OiCwTR?=	NX;2No9zW0GQR1XS
H-EMC-SS	NY\XOoVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLDUYc4UUN3ME2xOFYvQDFibl2=	NYDoWWp3W0GQR1XS
SK-MEL-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDyRWNKSzVyPUG0O{42PSCwTR?=	MXXTRW5ITVJ?
SK-N-FI	NVHSR4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXf1SFh3UUN3ME2xOFcvPTlibl2=	NGPwVnZUSU6JRWK=
NCI-H2126	M2\mVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LjT2lEPTB;MUS4MlE2KG6P	MVrTRW5ITVJ?
NCI-H1299	NI\ZTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTF3MD6yNkBvVQ>?	NH:zb\|BUSU6JRWK=
CFPAC-1	M1zJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mof3TWM2OD1zNUCuOlYhdk1?	NFHzNFRUSU6JRWK=
NCI-H661	NFfYZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF3MT6yOkBvVQ>?	NVz5Z41vW0GQR1XS
KYSE-70	M2C1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jRXWlEPTB;MUWxMlc6KG6P	NF61RYhUSU6JRWK=
SW900	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2SzXWlEPTB;MUW0MlY2KG6P	NV;B[VA3W0GQR1XS
Ca-Ski	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLRTWM2OD1zNU[uN\|khdk1?	NVP1bJRFW0GQR1XS
HPAF-II	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTF3Nj60O{BvVQ>?	M3nDXnNCVkeHUh?=
LB2518-MEL	NHzBTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXKZ3pKSzVyPUG1O{4yKG6P	NFW1RppUSU6JRWK=
LC-2-ad	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHqyWWhKSzVyPUG1PE43OiCwTR?=	MVjTRW5ITVJ?
HCC1806	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojYTWM2OD1zNkeuPFghdk1?	NHvDVnJUSU6JRWK=
UACC-62	NXe3UJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF4OD6wPUBvVQ>?	NVXiUHhYW0GQR1XS
KM-H2	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7udm1zUUN3ME2xO\|AvPThibl2=	NVLG[2xxW0GQR1XS
NCI-H2347	M1e5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDrVpdvUUN3ME2xO\|IvPzJibl2=	MmLRV2FPT0WU
SCC-15	NWnNNpNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTF5Mz62OkBvVQ>?	MnTmV2FPT0WU
BB49-HNC	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL5b2lWUUN3ME2xO\|MvQDFibl2=	NWX1UpU4W0GQR1XS
GMS-10	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPVeoJkUUN3ME2xO\|MvQTRibl2=	NYD4N3hRW0GQR1XS
NCI-H2052	NIO3NZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;J[WlEPTB;MUe0Mlkhdk1?	NUHTUJhjW0GQR1XS
SW626	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Hk[mlEPTB;MUe2MlA3KG6P	MkDLV2FPT0WU
MDA-MB-415	M2m2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTF5Nj62NUBvVQ>?	NWD2cGRWW0GQR1XS
Saos-2	M2nie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF5OT6zOUBvVQ>?	MoS1V2FPT0WU
DK-MG	M1S4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzTXmZRUUN3ME2xPFAvOyCwTR?=	MnrqV2FPT0WU
SNU-C2B	M4rXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjDeG11UUN3ME2xPFAvPzNibl2=	M2T6U3NCVkeHUh?=
A427	NILXb\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLJTWM2OD1zOEKuOVchdk1?	MV3TRW5ITVJ?
KP-N-YS	NVzveFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvCNFhKSzVyPUG4OUBvVQ>?	NUnKOogxW0GQR1XS
J82	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF6NT6xPEBvVQ>?	MnfQV2FPT0WU
LS-411N	M3;abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF6Nz6yPEBvVQ>?	NHr6OHhUSU6JRWK=
HCC1937	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLTSmhKSzVyPUG4O{41QSCwTR?=	NETBblhUSU6JRWK=
OE33	NVf5RYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHi0WXNKSzVyPUG4PE46PyCwTR?=	M2PXOnNCVkeHUh?=
NB7	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDWOpZvUUN3ME2xPFkvQDlibl2=	MnHRV2FPT0WU
SW684	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3pNo5VUUN3ME2xPVYvOTNibl2=	MkHsV2FPT0WU
HT-144	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXITINlUUN3ME2xPVYvOTVibl2=	NIjBZ2ZUSU6JRWK=
SK-MEL-30	M3f1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfIXWNVUUN3ME2xPVYvOiCwTR?=	MoTJV2FPT0WU
DBTRG-05MG	M3LUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPITWM2OD1zOUiuOFchdk1?	NHHXRpVUSU6JRWK=
NCI-H1395	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:2fXhKSzVyPUG5PE45PSCwTR?=	MXHTRW5ITVJ?
NCI-H2122	M2TDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTJyMD61PUBvVQ>?	MUPTRW5ITVJ?
no-10	NWTFSlJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIOzRoVKSzVyPUKwNU4xPCCwTR?=	M2rvN3NCVkeHUh?=
SW48	M1O3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXm4OXhRUUN3ME2yNFEvOzFibl2=	MlznV2FPT0WU
NCI-H1650	NUPyclRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJyND6wNUBvVQ>?	MmL3V2FPT0WU
MZ1-PC	NFj0bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPuSYhiUUN3ME2yNFUvPThibl2=	Mo[2V2FPT0WU
U-266	M2DLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJyNT63PUBvVQ>?	MX7TRW5ITVJ?
CAS-1	NU\6NYRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJyNz60OEBvVQ>?	MXHTRW5ITVJ?
AU565	NITrc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\xR3NpUUN3ME2yNVIvQDJibl2=	M4PPRnNCVkeHUh?=
UACC-257	NYjBWnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTJzMz65PUBvVQ>?	MkjrV2FPT0WU
CAL-27	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDXXYtyUUN3ME2yNVcvODVibl2=	NIfud4hUSU6JRWK=
NCI-H23	NYK4doxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfkXlBKSzVyPUKxPU4{OyCwTR?=	MoLmV2FPT0WU
TE-6	NETFPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nDXWlEPTB;MkG5MlY5KG6P	M4LTXHNCVkeHUh?=
TGBC24TKB	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{H5d2lEPTB;MkKyMlE4KG6P	NWnIVIJwW0GQR1XS
TE-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXQc5dKSzVyPUKyNk45QCCwTR?=	M3XRenNCVkeHUh?=
RCC10RGB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULPVoRoUUN3ME2yNlQvOTlibl2=	MWrTRW5ITVJ?
NCI-H596	NFP1UpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGryeHRKSzVyPUKyPE4zOiCwTR?=	M4PhTnNCVkeHUh?=
SW954	M4LnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJ\|Mz64N{BvVQ>?	M3i3PXNCVkeHUh?=
NCI-H2087	NV7jfoc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHpTYNKSzVyPUKzOE42OSCwTR?=	NX\2TWxOW0GQR1XS
SK-PN-DW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPwdmZFUUN3ME2yN\|UvOTlibl2=	M33NbXNCVkeHUh?=
KM12	NXPjWWVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rFS2lEPTB;MkO1Mlchdk1?	M{nTfnNCVkeHUh?=
BT-474	M3;jV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlq5TWM2OD1{M{WuO\|Mhdk1?	MVLTRW5ITVJ?
IST-MES1	M2jCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LjbGlEPTB;MkO2MlU4KG6P	NXXDR2t7W0GQR1XS
HT-1197	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGS3d2ZKSzVyPUKzPE4xQSCwTR?=	MXXTRW5ITVJ?
CAL-54	M2DzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrpUnRbUUN3ME2yN\|gvPDlibl2=	NYf4VGtKW0GQR1XS
NB10	M3u2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\DXYRUUUN3ME2yOFAvODZibl2=	M1\xSXNCVkeHUh?=
PANC-10-05	NWCzb5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHOyRmRKSzVyPUK0OU42PiCwTR?=	MYPTRW5ITVJ?
NCI-H522	M4P2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTYTWM2OD1{NEiuN\|Ehdk1?	M3LNR3NCVkeHUh?=
A388	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorUTWM2OD1{NEmuPFIhdk1?	NF;FSIFUSU6JRWK=
GOTO	M2PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjhTWM2OD1{NUCuNlkhdk1?	MmO4V2FPT0WU
KLE	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJ3MT64O{BvVQ>?	MYrTRW5ITVJ?
KYSE-520	NXrmZYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n5d2lEPTB;MkWyMlg3KG6P	NH7i[mVUSU6JRWK=
HCE-4	NYPYTXBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPze3BJUUN3ME2yOlIvPSCwTR?=	NXHMSFFqW0GQR1XS
KURAMOCHI	M4\PSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJ4NT65JI5O	Mn:4V2FPT0WU
HCC38	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGj4bohKSzVyPUK2Ok41QCCwTR?=	NHzYPWVUSU6JRWK=
FADU	NUXSbXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\qVlRKSzVyPUK2Ok43OyCwTR?=	NX\N[4ZzW0GQR1XS
CW-2	NUHKeJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTQTWM2OD1{NkmuPVYhdk1?	M4nUd3NCVkeHUh?=
L-428	NH\EVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPHTWM2OD1{N{WuNVUhdk1?	M13h[HNCVkeHUh?=
HCC1569	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;nPJpxUUN3ME2yO\|UvQDRibl2=	NW\u[lNJW0GQR1XS
NCI-H810	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJ5OD6zNUBvVQ>?	M1L5UnNCVkeHUh?=
LB771-HNC	NIPZXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJ6NT64OEBvVQ>?	NX7XVIJlW0GQR1XS
LCLC-103H	M13TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTJ6NT65PUBvVQ>?	NYO3UpdtW0GQR1XS
EFO-21	NXHidopuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGC2R2RKSzVyPUK4O{43QCCwTR?=	NILISJlUSU6JRWK=
CAL-72	NWj4TI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TPTmlEPTB;MkmzMlE6KG6P	MUjTRW5ITVJ?
SCC-9	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrZfodOUUN3ME2yPVMvOjJibl2=	MWXTRW5ITVJ?
COLO-829	M2jL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;oV2dIUUN3ME2yPVYvPSCwTR?=	MlHXV2FPT0WU
U-87-MG	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTNyMD63N{BvVQ>?	NYTRdlhtW0GQR1XS
MZ7-mel	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfvXlRKSzVyPUOyN{44PiCwTR?=	Mon6V2FPT0WU
NCI-H1770	M2G3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTN{Nj63OEBvVQ>?	MUPTRW5ITVJ?
ChaGo-K-1	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHq1[nBKSzVyPUOyPE4yKG6P	MWTTRW5ITVJ?
SiHa	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTN{OT6yOEBvVQ>?	M1:5PXNCVkeHUh?=
NCI-SNU-5	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTN\|Nj63O{BvVQ>?	NYq5VVZuW0GQR1XS
DJM-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmX5TWM2OD1\|NECuN\|Mhdk1?	NYW1VY13W0GQR1XS
OE19	M3zlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLCTWM2OD1\|NECuOVMhdk1?	NYmw[2lyW0GQR1XS
NCI-H1651	NI\kN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTN2ND6xPEBvVQ>?	NH\VcYhUSU6JRWK=
COLO-792	NHLMNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljHTWM2OD1\|NUSuOFIhdk1?	NUjnXWRoW0GQR1XS
ACHN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXXTlRKSzVyPUO1Ok44OSCwTR?=	MYHTRW5ITVJ?
TH-3	M3\j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTN5OT65OUBvVQ>?	MW\TRW5ITVJ?
HT-1376	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV6ySlN3UUN3ME2zPFQvQDhibl2=	MVXTRW5ITVJ?
RH-18	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTN7ND63OEBvVQ>?	MnvGV2FPT0WU
NB6	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN7Nj62OkBvVQ>?	NGG1RnRUSU6JRWK=
COLO-320-HSR	M4exVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzqRWJ5UUN3ME20NFMvOzdibl2=	NUn2XYpxW0GQR1XS
UACC-893	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\mcmlEPTB;NEC2MlQ4KG6P	NUC5V3o4W0GQR1XS
DSH1	NX7ub3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrBbWJKSzVyPUSwOk46OSCwTR?=	NHGxT4dUSU6JRWK=
TE-10	M4rNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTRyNz6wNUBvVQ>?	Mki0V2FPT0WU
HCC70	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrsfpB6UUN3ME20NFkvOjFibl2=	NX3VWXIxW0GQR1XS
TGBC11TKB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j2eWlEPTB;NEGwMlM{KG6P	M1;yOXNCVkeHUh?=
NCI-H727	NIfoRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTRzMj6xNUBvVQ>?	NUfoVJFJW0GQR1XS
ALL-PO	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\xRWlEPTB;NEG1MlY6KG6P	MYDTRW5ITVJ?
ABC-1	M{\oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4iweWlEPTB;NEKwMlQ2KG6P	MlG0V2FPT0WU
NCI-H69	M4Dld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTR{Nj63OkBvVQ>?	NHK5[WVUSU6JRWK=
GP5d	NFL1dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnOUWV[UUN3ME20N\|QvPDFibl2=	M2S3U3NCVkeHUh?=
UMC-11	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoW5TWM2OD12NUiuN\|Yhdk1?	NWq2V4tZW0GQR1XS
RMG-I	M1PoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTR4Nz61OkBvVQ>?	NFu4eZhUSU6JRWK=
YAPC	M{XEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTL[G9KSzVyPUS5NE43KG6P	NWPVVnB5W0GQR1XS
LS-1034	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTWbZd3UUN3ME20PVEvODZibl2=	M1\SfXNCVkeHUh?=
RCM-1	NVXzb5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXITWM2OD12OU[uOlghdk1?	NHTjNGlUSU6JRWK=
HCC1954	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfndlBNUUN3ME21NVIvPSCwTR?=	NWq5UI1jW0GQR1XS
SK-MEL-24	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGP0SZRKSzVyPUWxOk42OSCwTR?=	NWeyPVVNW0GQR1XS
NB12	NXywNHROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXG[YFKSzVyPUWyPE41OiCwTR?=	M3LGfnNCVkeHUh?=
SW756	M{PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3uyWGlEPTB;NUW0Mlk3KG6P	MmTUV2FPT0WU
HCC1187	NYHLXnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTV5NT64N{BvVQ>?	MnHBV2FPT0WU
NCI-H2342	NXHZemdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETLfoVKSzVyPUW5NE4{QSCwTR?=	NWXmV3N2W0GQR1XS
NCI-H2291	M{\OSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;nc2lEPTB;NUm4MlMyKG6P	NFX0NYhUSU6JRWK=
OVCAR-3	NFXrT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHtTWM2OD13OUiuPVYhdk1?	M2DDbHNCVkeHUh?=
MHH-NB-11	M1XEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrtRXpKSzVyPU[yPU4xOSCwTR?=	MoDaV2FPT0WU
SAS	NV\5N5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HLR2lEPTB;NkWyMlY4KG6P	MYrTRW5ITVJ?
COLO-824	NHL3ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvUToNtUUN3ME22PFkvOzdibl2=	MXrTRW5ITVJ?
HCC1395	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTZ7OD61JI5O	MYrTRW5ITVJ?
COLO-668	M3zKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTdyNj6xJI5O	M{njVXNCVkeHUh?=
NCI-H226	M1HrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDWWHZCUUN3ME23NFcvQCCwTR?=	MnzKV2FPT0WU
NB17	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLyTWM2OD15MkGuO\|Uhdk1?	MoTNV2FPT0WU
SW1463	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTd\|OT6xPUBvVQ>?	NEHT[3BUSU6JRWK=
TGW	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFThVoFKSzVyPUe2NE4yPSCwTR?=	NX\EVYhuW0GQR1XS
NCI-H526	NGjUeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFeycGpKSzVyPUiyN{42OyCwTR?=	NEXiN4JUSU6JRWK=
COR-L88	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIm1UWdKSzVyPUi0PE4yOiCwTR?=	M3zmZ3NCVkeHUh?=
NCI-H441	M2jDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTh7NT6yNkBvVQ>?	NIjDW4pUSU6JRWK=
NCI-H630	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\MRWlEPTB;OUGyMlk3KG6P	MVLTRW5ITVJ?
Mo-T	NHzYUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7oTWM2OD17NEeuPFghdk1?	MWrTRW5ITVJ?
JAR	M3jtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvKTWM2OD17NU[uNlQhdk1?	M4XNNXNCVkeHUh?=
NCI-H1838	M1nrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vPXmlEPTB;MT6wNlM5QCEQvF2=	NWjZWI5tW0GQR1XS
DoTc2-4510	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nPU2lEPTB;MT6wO\|M4PiEQvF2=	M3TEcnNCVkeHUh?=
MKN28	NVHwZnpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHOc4dKSzVyPUGuNFkxOjRizszN	MYTTRW5ITVJ?
HuP-T3	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS3c2FKSzVyPUGuNVE6ODVizszN	MXXTRW5ITVJ?
TE-9	M2jQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFwMUK5O\|Mh\|ryP	M2X2Z3NCVkeHUh?=
NY	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrGXmlyUUN3ME2xMlE3Pzl{IN88US=>	M33wRnNCVkeHUh?=
HT55	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWCwe4ZHUUN3ME2xMlMyOzR2IN88US=>	MUXTRW5ITVJ?
SW837	NVO5N\|hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwM{K5O\|gh\|ryP	M4XaWnNCVkeHUh?=
NCI-H2029	NHfsbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:wZZV1UUN3ME2xMlQyPzlzIN88US=>	MnfOV2FPT0WU
IST-SL1	NUPQSWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFH0PWJKSzVyPUGuOFQzPCEQvF2=	NUS1OlQzW0GQR1XS
COLO-741	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLyT3dbUUN3ME2xMlQ6PzdzIN88US=>	Mk[3V2FPT0WU
LU-65	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkX0TWM2OD1zLk[yNlQ6KM7:TR?=	MX7TRW5ITVJ?
NCI-H1304	NFzsdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP5TWM2OD1zLk[1OFk5KM7:TR?=	M1zmNXNCVkeHUh?=
KARPAS-299	M2nPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwN{m0O\|kh\|ryP	MnviV2FPT0WU
NCI-H358	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TSNmlEPTB;MT65OVUxOyEQvF2=	NFH5dpJUSU6JRWK=
OAW-28	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M122Z2lEPTB;Mj6wOlkyQSEQvF2=	NHjZXXBUSU6JRWK=
C8166	M1LyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\4TWM2OD1{Lk[zN\|kzKM7:TR?=	NHm2U4tUSU6JRWK=
COLO-678	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;CTWM2OD1{LkizO\|Y5KM7:TR?=	MnLaV2FPT0WU
SK-N-DZ	NIHIenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJwOE[zPFEh\|ryP	NUPJeJg4W0GQR1XS
NCI-H82	NWn4fotnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TQcWlEPTB;Mj65NFM3QSEQvF2=	NXrYR3lIW0GQR1XS
JVM-2	M2P3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTNwMEOxPFgh\|ryP	NHnjZVhUSU6JRWK=
SW1116	NIj4eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYC1bFA6UUN3ME2zMlA2PDFzIN88US=>	MULTRW5ITVJ?
MDA-MB-453	NXvqeHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTNwMUC0N\|kh\|ryP	Mn:5V2FPT0WU
Calu-6	NI[xZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfvR4hwUUN3ME2zMlE6QTdizszN	MlXFV2FPT0WU
SHP-77	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LIeWlEPTB;Mz61Nlgh\|ryP	NYPRcVVFW0GQR1XS
Capan-2	M4LDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XNNmlEPTB;ND6zNlU5OSEQvF2=	MmruV2FPT0WU
SW948	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfkZXJKSzVyPUSuO\|Q4PzlizszN	NF;6[5BUSU6JRWK=
HDLM-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrqTWM2OD13LkC3O\|I2KM7:TR?=	M4C4PXNCVkeHUh?=
LAN-6	M4rTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTZwMkG0PVUh\|ryP	NVi1NHFVW0GQR1XS
LU-135	NF7JWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUm4bY1HUUN3ME22MlQ{ODd5IN88US=>	NVq1em4{W0GQR1XS
T84	NGOxZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPWWpZVUUN3ME22Mlk5PjRizszN	NXL0cXBjW0GQR1XS
CAPAN-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF[3UYFKSzVyPUeuOlIzOzNizszN	MnzkV2FPT0WU
SW1417	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVv1UJdtUUN3ME23MlkyPzNzIN88US=>	MX7TRW5ITVJ?
BALL-1	NYPtcGFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHkUpZKSzVyPUiuOVA1ODlizszN	Ml3JV2FPT0WU
HT-29	NUDQemJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTlwMEe1PVkh\|ryP	NIWyV4dUSU6JRWK=
C3A	NHvPdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTlwOEizPVQh\|ryP	MmHSV2FPT0WU
NCI-H1993	NHjaXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HOR2lEPTB;MUCuOVA5OSEQvF2=	M4H3O3NCVkeHUh?=
SK-MEL-1	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjVPJNKSzVyPUGxMlYzQDlizszN	Mn\wV2FPT0WU
DU-145	NETPd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjmbGRoUUN3ME2xOE42ODV{IN88US=>	NIn1PHdUSU6JRWK=
KP-N-YN	NGjCOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD3WFZKSzVyPUG0MlUyODNizszN	MkfSV2FPT0WU
CCRF-CEM	M2LneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTF2Lke4NFkh\|ryP	M1Pq[nNCVkeHUh?=
ZR-75-30	NH7lR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;TS2lEPTB;MU[uN\|MxOyEQvF2=	M1Hne3NCVkeHUh?=
A673	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrvOIJKSzVyPUKwMlU2ODdizszN	M4\mUHNCVkeHUh?=
K-562	NHHjem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTzTWM2OD1{OD60NVg{KM7:TR?=	M4LHV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

体内研究

BEZ235诱导肿瘤(69%)消退，而对体重增加没有统计学上显著的作用。总之，这些初步的体内功效研究结果表明，BEZ235单一口服给药时能够阻断疾病的发展，与其他抗癌药结合使用时能够增强疗效。^[1]

激酶实验： ^[2]	- 合并体外蛋白激酶,PI3K,和mTOR实验: PI3Kα, β, δ蛋白都由与p110全长蛋白相接的p85 N端的iSH2域组成，只是PI3Kα没有最后的20个氨基酸。PI3Kγ由p110全长蛋白去掉前144个氨基酸产生而来。所有PI3K蛋白在羧基末端加组氨酸标签便于纯化，然后克隆到pBlue-Bac4.5 (用于α, β,和δ亚型) 或者pVL1393 (用于γ 亚型) 质粒中。转染BaculoGold WT基因组DNA的不同的载体按说明书推荐的方法生产各自重组体杆状病毒及重组蛋白。使用激酶发光检测试剂盒测定BEZ235 (NVP-BEZ235)作用于PI3K的活力。在384孔板上进行激酶实验。在每个孔中加入50 nl的测试项目（溶在90%DMSO中）和5ul的反应buffer,反应buffer包含10 μg/ml PI基质 (l-α-磷脂酰肌醇; 由Avanti Polar Lipids提供;预备在3%辛基葡萄糖苷中)，然后加入PI3K 蛋白(p110α, p110β, p110δ,和p110γ分别为10, 25, 10,和150 nM)。加入预备在反应buffer中的5 ul 1 µM 的ATP反应开始，反应进行60分钟 (测p110α, p110β, p110δ)或者120分钟(测p110γ)，随后加入10ul的荧光激酶buffer终止反应。数据用Synergy 2 阅读器阅读用于荧光测试。
细胞实验： ^[1]	- 合并 Cell lines: HCT116, DLD-1, SW480 Concentrations: 0-1 μM Incubation Time: 48小时 Method: HCT116 (PIK3CA突变型; 激酶域在H1047R), DLD-1 (PIK3CA突变型；螺旋域在E545K), SW480 (PIK3CA 野生型)人类CRC细胞系，同基因型的DLD-1 PIK3CA突变和野生型细胞培养在含10%FBS和1×青霉素/链霉素的培养基中。细胞按不同的初始密度加入（HCT116: 3000个细胞/每孔, DLD-1: 5500个细胞/每孔, SW480: 4500个细胞/每孔, DLD-1 PIK3CA突变型: 7000个细胞/每孔, DLD-1 PIK3CA野生型: 9000个细胞/每孔)，用来计算不同的生长动力学。16个小时后，细胞加入浓度越来越高的BEZ235中进行温育，含有药物的培养基24小时更换一次。根据产品说明书，加入细胞16小时和药物处理48小时，使用单溶液细胞增殖检测试剂盒以比色法检测细胞活力。与没有用药物处理正在生长的细胞相比，药物处理的细胞的活力也逐渐趋于正常化。使用GraphPad Prism 5软件用4个参数的回归曲线计算IC50值。用于western blot 分析，细胞用0 nM 或者最高抑制剂量(500 nM) BEZ235处理 2, 6, 24, 或者48 小时。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 雌性Harlan无胸腺裸鼠 Formulation: NMP/聚乙二醇300(10/90,v/v) Dosages: 45 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： NMP+PEG300 (10+90, v+v)	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dactolisib (BEZ235) SDF

分子量	469.55
化学式	C₃₀H₂₃N₅O
CAS号	915019-65-7
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	NVP-BEZ235

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012

研究领域

产品类型

Dactolisib (BEZ235)

客户使用Selleck生产的Dactolisib (BEZ235)发表文献258篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dactolisib (BEZ235) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)